Skip to content

罗氏控股

US · RHHBY #49 按市值排名 上市于 1970
57.14 +0.36 +0.63%
实时 - 追踪5344个代码 - 心跳于385秒前 · 2026-10-17 16:10

最新新闻

  • Morgan Stanley Upgrades ROCHE HOLDING AG(RHHBY.US) to Buy Rating, Raises Target Price to $507.41
    \u5e02\u573a\u8d44\u8baf · 2026/8/7
  • 评级变动
    TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $67
    \u5e02\u573a\u8d44\u8baf · 2026/2/11
  • 评级变动
    HSBC Maintains ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Raises Target Price to $57
    \u5e02\u573a\u8d44\u8baf · 2025/12/10
  • 评级变动
    HSBC Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $50
    \u5e02\u573a\u8d44\u8baf · 2025/10/2
  • 评级变动
    The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
    Zhitong Finance · 2024/8/19
  • 评级变动
    Argus Research Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $55
    \u5e02\u573a\u8d44\u8baf · 2026/4/6
  • 评级变动
    TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $43
    \u5e02\u573a\u8d44\u8baf · 2025/7/24
  • 评级变动
    Goldman Sachs Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating
    \u5e02\u573a\u8d44\u8baf · 2026/1/16
  • The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.
    Zhitong Finance · 2026/9/4
  • Roche (RHHBY.US) submits BTK inhibitor for market approval
    Zhitong Finance · 2026/9/30
  • 评级变动
    Morgan Stanley Initiates ROCHE HOLDING AG(RHHBY.US) With Sell Rating, Announces Target Price $46
    \u5e02\u573a\u8d44\u8baf · 2026/4/7
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Roche Holding (RHHBY)
    TipRanks · 2025/12/6
  • 评级变动
    TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Raises Target Price to $67
    \u5e02\u573a\u8d44\u8baf · 2026/2/10
  • Roche (RHHBY.US) reports positive mid-stage trial results for its weight-loss injection: average weight reduction of 15.5% over 48 weeks, with a 2.65% decrease in blood glucose indicators.
    Zhitong Finance · 2026/9/22
  • 评级变动
    Barclays Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/1/7
  • 评级变动
    Erste Group Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating
    \u5e02\u573a\u8d44\u8baf · 2024/11/5
  • From treatment to prevention! Roche (RHHBY.US) initiates clinical trial of Brainshuttle therapy for Alzheimer's disease
    Zhitong Finance · 2026/7/15

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-17 16:10:31 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

罗氏控股 讨论区 1 条评论

  1. diagnostics arm doesn’t get enough credit next to the pharma pipeline headlines. currency moves swing the adr price more than the underlying business most quarters.

发表评论